SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 332 filers reported holding SEATTLE GENETICS INC in Q3 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $3,907,000 | +89.4% | 22,994 | +28.6% | 0.04% | +56.5% |
| Q1 2020 | $2,063,000 | +13.0% | 17,883 | +11.9% | 0.02% | +43.8% |
| Q4 2019 | $1,826,000 | +39.5% | 15,983 | +4.3% | 0.02% | +33.3% |
| Q3 2019 | $1,309,000 | +13.5% | 15,325 | -8.0% | 0.01% | +9.1% |
| Q2 2019 | $1,153,000 | -18.6% | 16,664 | -13.8% | 0.01% | -21.4% |
| Q1 2019 | $1,416,000 | +25.3% | 19,334 | -3.1% | 0.01% | +7.7% |
| Q4 2018 | $1,130,000 | -26.5% | 19,943 | 0.0% | 0.01% | -7.1% |
| Q3 2018 | $1,538,000 | +76.8% | 19,943 | +52.2% | 0.01% | +55.6% |
| Q2 2018 | $870,000 | +3246.2% | 13,100 | +2520.0% | 0.01% | – |
| Q1 2018 | $26,000 | -59.4% | 500 | -58.3% | 0.00% | -100.0% |
| Q4 2017 | $64,000 | -1.5% | 1,200 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $65,000 | +150.0% | 1,200 | +140.0% | 0.00% | – |
| Q2 2017 | $26,000 | -16.1% | 500 | 0.0% | 0.00% | – |
| Q1 2017 | $31,000 | +19.2% | 500 | 0.0% | 0.00% | – |
| Q4 2016 | $26,000 | -3.7% | 500 | 0.0% | 0.00% | – |
| Q3 2016 | $27,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 51,049,760 | $3,738,884,000 | 23.93% |
| Lagoda Investment Management, L.P. | 76,873 | $5,630,000 | 7.16% |
| Matrix Capital Management Company, LP | 3,141,852 | $230,109,000 | 6.14% |
| DOMINI IMPACT INVESTMENTS LLC | 3,120 | $229,000 | 3.51% |
| Opus Point Partners Management, LLC | 17,832 | $1,306,000 | 1.77% |
| Capital International Sarl | 188,200 | $13,784,000 | 1.72% |
| EMORY UNIVERSITY | 33,368 | $2,444,000 | 1.72% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,900 | $4,460,000 | 1.65% |
| CAPITAL GUARDIAN TRUST CO | 1,358,254 | $99,415,000 | 1.32% |
| Rhenman & Partners Asset Management AB | 150,598 | $11,030,000 | 1.29% |